Stocks
AbbVie’s Skyrizi Expands Pediatric Indication to Psoriatic Diseases
AbbVie's Skyrizi has received US FDA approval for children aged six and older with moderate-to-severe plaque psoriasis or active psoriatic arthritis. This...
#pharmaceuticals 22 articles
Stocks
Definium Therapeutics Prices $700M Public Offering
Definium Therapeutics announced the pricing of an upsized public offering, raising approximately $700 million in gross proceeds.
Stocks
FDA Greenlights uniQure’s AMT-130 Data for Accelerated Approval Filing
uniQure's stock surged after the FDA indicated that three-year Phase I/II data for its Huntington's disease gene therapy, AMT-130, could support an...
Stocks
Biogen Acquires RayThera for Up to $1 Billion, Bolstering Immunology Pipeline
Biogen Inc. announced an agreement to acquire private biotech RayThera Inc. for up to $1 billion, significantly expanding its immunology portfolio with...
Stocks
GSK, Incyte, OpenAI Lead Week’s Key Business Deals
Major transactions and discussions marked the week, with GSK, Incyte, Ingredion, and OpenAI among the notable players. Roku's potential sale also generated...
Stocks
Apotex IPO Raises C$1.3 Billion, Canada’s Largest Since 2021
Apotex Health Corp. and its backers secured C$1.3 billion ($932 million) in a Toronto IPO, pricing shares at the top end of...
Stocks
Lilly’s Retatrutide Shows Broad Benefits in Obesity Trials
Eli Lilly's experimental obesity drug retatrutide delivered positive late-stage trial results, showing substantial weight loss and improvements in type 2 diabetes, knee...
Markets
Three Dividend Giants for $10,000 as Tech Cools
As investors rotate out of technology, three dividend-growth stocks—AbbVie, Procter & Gamble, and Enterprise Products Partners—offer stability and attractive yields for a...
Stocks
NervGen Pharma Prices $60 Million Public Offering
NervGen Pharma Corp. has priced a public offering of common shares and warrants, raising $60 million to advance its neuroreparative therapeutics.